HAHelene Alexanderson

Helene Alexanderson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Helene Alexanderson has a total of 103 co-authors. Here are the top co-authors by number of shared publications:

  • Ingrid E. Lundberg

    Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet Stockholm Sweden

    7 shared publications
  • Cecilia Leijding

    Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden

    5 shared publications
  • Daniel C. Andersson

    Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden

    5 shared publications
  • Kristofer M. Andreasson

    Department of Medicine, Solna, Division of Rheumatology, Karolinska Institutet, Stockholm, Sweden; Karolinska University Hospital, Women's Health and Allied Health Professionals Theme, Medical Unit Allied Health Professionals, Stockholm, Sweden

    5 shared publications
  • Maryam Dastmalchi

    Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden; Department of Medicine, Solna, Division of Rheumatology, Karolinska Institutet, Stockholm, Sweden; Department of Gastro, Dermatology and Rheumatology, Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden

    5 shared publications
  • Stefano Gastaldello

    Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden

    5 shared publications

Latest Publications

  • Open Access

    Validation of the Paediatric Nijmegen Questionnaire in Sweden: A Self‐Screening Tool for Dysfunctional Breathing

    by Eleni Theofanidou‐Axelsson, Malin Nygren‐Bonnier, Björn Nordlund, Henrik Ljungberg, Helene Alexanderson

    Background: The Nijmegen Questionnaire (NQ) is used to identify Dysfunctional Breathing (DB) in individuals with asthma. However, it has not been validated for use in children and adolescents. Objective: This study aimed to validate a Swedish NQ for this population. Methods: Participants aged 10–17 years with asthma were included ( n = 124). In Cohort I ( n = 22), audiotaped semi‐structured interviews were conducted to adapt and refine the questionnaire analyzed by qualitative content analysis, resulting in NQ version 1. Forty‐eight participants (11 from Cohort I, 37 new) then completed version 1 to assess internal redundancy, consistency (Spearman's Rho, Cronbach's alpha) and item clarity, leading to version 2. Cohort II ( n = 60 new) completed NQ version 2 alongside the Paediatric Asthma Quality of Life Questionnaire (PAQLQ) and Childhood/Adult Asthma Control Test (cACT/ACT) to assess construct validity. Cohort III ( n = 54, 48 from Cohort II, 6 new) completed NQ version 2 again after 2 weeks for test–retest reliability. Results: Content analysis prompted revisions for clarity and relevance. Internal redundancy ranged from r s = 0.00–0.69 and internal consistency was 0.85 (Cronbach's alpha). The NQ correlated moderately with cACT/ACT (r s = −0.54) and PAQLQ subscales Symptoms, Activity limitation and Emotional function, r s −0.52, −0.48, −0.39 (CI 0.32;0.70, 0.24;0.66, 0.14;0.60) respectively. Test–retest reliability was 0.86 (Kw) ( p < 0.0001). Conclusion: The Swedish Paediatric NQ seems to be a valid and reliable tool for identifying DB in children and adolescents with asthma.

  • Open Access

    A randomized, phase IIa treatment delayed-start trial of the oral JAK 1/2 inhibitor, baricitinib, in adult idiopathic inflammatory myopathy

    by Ashma Krishan, Luke Tomlinson, James B Lilleker, Gema Sylvestre Garcia, Andrew Snedden, Mohammed Zubair, Patrick Gordon, Athiveeraramapandian Prabu, Sarah Tansley, Aamir Aslam, et al.

    Objectives To assess the effects of 24 weeks active treatment with baricitinib, a JAK1/2 inhibitor, in adult idiopathic inflammatory myopathy (IIM). Methods Patients with active dermatomyositis (DM) or polymyositis (PM) were enrolled into a 1:1 randomized treatment delayed-start design clinical trial ( NCT04208464 ). Participants received 24 weeks baricitinib plus 12 weeks follow-up (Immediate-start), or 12 weeks standard of care plus 24 weeks baricitinib (Delayed-start). The primary outcome was clinical response after 24 weeks active treatment, defined as minimal improvement (Total Improvement Score >20 [TIS20]). Secondary outcomes included: TIS40 (moderate), TIS60 (major) response, between-arm comparison, time to achieve response, change in clinical outcome measures. steroid-sparing and cumulative adverse events. Results 14/15 (93%) randomized participants (mean age 43.2 years [11.6 SD]; 13 DM, 2 PM; 11 female) completed the study (baseline to 36 weeks) and all achieved TIS20 at 24 weeks post-active treatment (95% exact CI 0.68-1.00). 9/15 (60%) achieved TIS40 response and 2/15 (13%) TIS60 response. At 12 weeks post-randomization, 11/15 (73%) patients achieved at least TIS20 (95%CI 0.45-0.92), including all Immediate-start arm patients and four Delayed-start arm patients. At the same time point, evidence of a difference was noted for patient global, extramuscular, CDASI skin activity, pain, fatigue and SF-36 mental/physical health scores. Two hospitalisation serious adverse events were documented, neither related to study drug. Conclusions Treatment of IIM with baricitinib resulted in improved clinical outcome after 24 weeks. Significant improvement after 12 weeks treatment was also evident. No significant safety concerns were raised. A randomized placebo-controlled trial is needed to confirm the efficacy in patients with IIM.

  • Open Access

    Ultrasonographic assessment of the diaphragm in systemic lupus erythematosus: cut-off values and predictive indicators of diaphragm thickness

    by Fulden Sari, Zeliha Çelik, Deran Oskay, Nevin Aysel Güzel, Seriyye Allahverdiyeva, Halit Nahit Şendur, Şenol Çelik, Helene Alexanderson, Abdulsamet Erden, Abdurrahman Tufan

    Background: Respiratory complications significantly result in morbidity and mortality in patients with Systemic Lupus Erythematosus (SLE). However, the impact of SLE on respiratory muscle function, particularly diaphragm thickness and strength, has been the subject of limited investigation. Aims: The study aims to investigate the key physiological and respiratory parameters affecting diaphragm thickness in SLE patients and to assess its role as a predictive indicator of respiratory dysfunction. Methods: The cross-sectional study included 29 patients with SLE and 48 healthy individuals. Diaphragm muscle thickness in both the inspiration and expiration phases was evaluated by ultrasonography. Fatigue, self-reported physical activity, pulmonary function tests, and respiratory muscle strength were assessed in the study. Results: Diaphragm thickness during inspiration and expiration phases, along with maximal inspiratory pressure (MIP) values, fatigue, and physical activity levels, were significantly lower in SLE patients compared to healthy controls ( p < 0.05). Diaphragm thickness during the inspiratory phase showed a strong association with key pulmonary function parameters, particularly the FEV₁/FVC% and FEV₁%, while during expiration, it was mainly influenced by the FEV₁/FVC% and FVC%. Maximal expiratory pressure had a greater impact on diaphragm thickness compared to MIP. In SLE patients, the optimal cut-off values for diaphragm thickness were 1.50 mm during inspiration and 1.075 mm during expiration. Conclusion: These findings provide valuable information on diaphragm functionality and establish a strong foundation for clinical applications, emphasizing the potential of predictive models in diagnosing and managing respiratory dysfunction.

  • Open Access

    Inhibition of the type I interferon receptor pathway protects against muscle weakness induced by dermatomyositis serum

    by Suchada Kaewin, Cecilia Leijding, Stefano Gastaldello, David Makari, Yi Zhong, Kristofer M. Andreasson, Kent Jardemark, Maryam Dastmalchi, Begum Horuluoglu, Helene Alexanderson, et al.


  • Top Cited Papers
    Open Access

    Sera from patients with dermatomyositis and antisynthetase syndrome mediate muscle weakness, impair mitochondrial respiration and induce local cytokine production in muscle tissue

    by Cecilia Leijding, Stefano Gastaldello, Tomas Schiffer, Suchada Kaewin, Kristofer M. Andreasson, Yi Zhong, Begum Horuluoglu, Maryam Dastmalchi, Antonella Notarnicola, Angeles S. Galindo-Feria, et al.


  • Open Access

    High-intensity interval training outperforms moderate exercise to improve aerobic capacity in patients with recent-onset idiopathic inflammatory myopathies: a multicentre randomised controlled trial

    by Kristofer M. Andreasson, Cecilia Leijding, Maryam Dastmalchi, Antonella Notarnicola, Stefano Gastaldello, Takashi Yamada, Heléne Sandlund, Dag Leonard, Håkan Westerblad, Ingrid E. Lundberg, et al.


  • Open Access

    High-Intensity Interval Training Outperforms Moderate Exercise to Improve Aerobic Capacity in Patients with Recent-Onset Idiopathic Inflammatory Myopathies: A Multicenter Randomized Controlled Trial

    by Kristofer M. Andreasson, Cecilia Leijding, Maryam Dastmalchi, Antonella Notarnicola, Stefano Gastaldello, Takashi Yamada, Heléne Sandlund, Dag Leonard, Håkan Westerblad, Ingrid E. Lundberg, et al.

    Objective: To investigate efficacy, safety, and tolerance of high-intensity interval training (HIIT) versus standard low-moderate intensity home-based exercise (CON) to improve aerobic capacity, muscle endurance, and mitochondrial function in patients with recent onset, idiopathic inflammatory myopathies (IIM). Methods: Twenty-three patients with recent onset IIM were randomized into two groups: HIIT and CON. HIIT underwent 12 weeks of supervised high-intensity training, while CON followed a low-moderate intensity home-based exercise program. Outcomes included maximal exercise test (VO 2 peak, peak power, time-to-exhaustion (TTE)), mitochondrial protein expression in muscle biopsy serum levels of muscle enzymes (CK, LD, AST, ALT), muscle strength (MMT8) and disease activity (subset of MDAAT), before and after intervention. Results: HIIT resulted in a 16 % increase in VO 2 peak L/min, significantly higher than the 1.8 % change in CON (95 % CI 0.1;0.47). Peak power and TTE also improved significantly more in HIIT, 18 % and 23 %, respectively, compared to CON, 8 % and 12 %, (95 % CI 3.9;30.8 and 00:06;03:18, respectively). Muscle biopsies (HIIT n=7, CON n=6) showed increases (p The study was registered at ClinicalTrials.gov : NCT03324152 Significance and Innovations: High-intensity interval training (HIIT) is more effective to improve aerobic capacity (peak oxygen uptake; VO 2 peak), increasing 16 % compared to 1.8 % change in the moderate exercise control group in patients with recent onset IIM. HIIT produced larger exercise adaptations with increased expression of aerobic metabolism (mitochondrial) proteins in muscle tissue compared to moderate exercise. HIIT is a safe and well tolerated exercise intervention for patients with recent onset IIM.


  • Open Access

    Exercise for improving bone health in patients with AIRDs: Understanding underlying biology and physiology

    by Ilke Coskun Benlidayi, Latika Gupta, Jasmine Parihar, Aviya Lanis Levy, Helene Alexanderson

    Exercise has numerous health benefits in patients with autoimmune inflammatory rheumatic diseases (AIRDs). Regular physical activity can help maintain/improve bone health. The aim of the present article was to review current knowledge on the effects of exercise on bone health in patients with AIRDs, particularly in those experiencing a high corticosteroid burden. The article also aimed to discuss potential mechanisms underlying the benefits of physical activity/exercise on bone tissue. Potential explanations regarding the role of exercise on bone health in AIRDs include anti‐inflammatory effects, mechanical loading, improvement in muscle strength, hormonal changes, improvement in balance, and effects on telomere erosion, deoxyribonucleic acid methylation, and gene expression. Current evidence regarding the outcomes of exercise on bone health in patients with AIRDs is predominantly derived from studies focused on rheumatoid arthritis. Expanding research to include other rheumatic conditions would enhance the overall understanding of this topic.